Related Experiment Video
Updated: Oct 20, 2025
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
Cardioprotective Roles of Endothelial Progenitor Cell-Derived Exosomes
Cai-Yu Zeng1,2,3, Jia Xu1,2,3, Xin Liu1,2,3
1Department of Emergency Medicine, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Insights
Cardiovascular disease therapies show promise with endothelial progenitor cell-derived exosomes (EPC-EXs). These exosomes offer protective effects against heart and blood vessel conditions through various mechanisms.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Cell Biology
Background:
- Cardiovascular diseases (CVDs) are a leading cause of global mortality.
- Endothelial progenitor cell (EPC) transplantation is a promising CVD therapy, primarily via paracrine factors.
- EPCs release exosomes (EPC-EXs), nano-sized vesicles containing bioactive molecules.
Purpose of the Study:
- To review the therapeutic potential of EPC-derived exosomes (EPC-EXs) for cardiovascular diseases (CVDs).
- To detail the mechanisms of action of EPC-EXs in promoting CVD prognosis.
- To highlight EPC-EXs as a cell-free therapeutic strategy.
Main Methods:
- Literature review of studies on EPC-EXs and their therapeutic effects.
- Analysis of mechanisms including anti-inflammation, anti-oxidation, and anti-apoptosis.
- Examination of EPC-EXs' roles in inhibiting endothelial-to-mesenchymal transition (EndMT) and fibrosis.
Main Results:
- EPC-EXs exert protective effects on the heart and blood vessels.
- Identified mechanisms include anti-inflammatory, anti-oxidative, and anti-apoptotic properties.
- EPC-EXs demonstrate potential in inhibiting EndMT, cardiac fibrosis, and vascular remodeling while promoting angiogenesis.
Conclusions:
- EPC-derived exosomes (EPC-EXs) represent a promising cell-free therapeutic approach for cardiovascular diseases (CVDs).
- Their multifaceted mechanisms of action offer significant potential for improving CVD prognosis.
- Further research into EPC-EXs could advance regenerative medicine strategies for cardiovascular conditions.
Abstract:
With the globally increasing prevalence, cardiovascular diseases (CVDs) have become the leading cause of mortality. The transplantation of endothelial progenitor cells (EPCs) holds a great promise due to their potential for vasculogenesis, angiogenesis, and protective cytokine release, whose mechanisms are essential for CVD therapies. In reality, many investigations have attributed the therapeutic effects of EPC transplantation to the secretion of paracrine factors rather than the differentiation function. Of note, previous studies have suggested that EPCs could also release exosomes (diameter range of 30-150 nm), which carry various lipids and proteins and are abundant in microRNAs. The EPC-derived exosomes (EPC-EXs) were reported to act on the heart and blood vessels and were implicated in anti-inflammation, anti-oxidation, anti-apoptosis, the inhibition of endothelial-to-mesenchymal transition (EndMT), and cardiac fibrosis, as well as anti-vascular remodeling and angiogenesis, which were considered as protective effects against CVDs. In this review, we summarize the current knowledge on using EPC-EXs as therapeutic agents and provide a detailed description of their identified mechanisms of action to promote the prognosis of CVDs.
More Related Videos
08:43Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery
Published on: February 14, 2017
07:26Isolation of Endothelial Progenitor Cells from Human Umbilical Cord Blood
Published on: September 14, 2017
Related Concept Videos
01:36Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
01:19Clinical Applications of Epidermal Stem Cells
01:19Mesenchymal Stem Cells